A Phase 3 interventional study of Erector spinae plane block and Levobupivacaine 0,25% in Pain, Postoperative, Anaesthesia and Surgery, sponsored by Dr M. B. Breebaart. Status unknown at 2 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-05.
Sponsored by Dr M. B. Breebaart · Phase 3, Interventional, and Treatment
Title:
A prospective randomized double blind trial of the efficacy of a bilateral lumbar erector spinae block on the 24 h morphine consumption after posterior lumbar interbody fusion surgery.
Objectives:
The primary objective is to study the influence of a bilateral erector spinae block on 24h morphine consumption.
Endpoint:
The primary endpoint is the 24 h morphine consumption in mg. Secondary endpoints are intraoperative sufentanil requirement, total morphine during first 72 postoperative hours, NRS pain scores in rest and defined movement (moving to chair) at regular time intervals and Quality of Recovery 40 score (QoR-40) at fixed time intervals day 1 and 3 postoperatively
Population:
Patients undergoing posterior lumbar interbody fusion ranging 1 - 3 levels Phase 3
Number of sites Enrolling participants:
University Hospital Antwerp \&AZ KLINA Brasschaat
Description of study agent:
Bilateral erector spinae block: each block contains 20 ml levobupivacaine 0.25% + 5 mcg/ml epinephrine Study duration Until the required study population is met Participant duration 72 hours
In this prospective randomized double blind placebo controlled clinical trial we would like to assess the efficacy of a bilateral lumbar erector spinae block on the 24h morphine consumption after posterior lumbar interbody fusion surgery. Patients scheduled for 1-2 level PLIF surgery will be recruited in AZ KLINA in Brasschaat and the University Hospital Antwerp in Edegem. The study contains two arms. Subjects will be randomly allocated to an erector spinae block group or the sham block group (placebo).
Stratified randomization will be done according to gender, levels of surgery and site online with Q minim.The study medication will be prepared in identical premade syringes and numbered according to a computer generated block randomization list (1:1 ratio ESB:sham). Subjects will be assigned consecutive numbers upon inclusion to the study and receive the study medication from the corresponding numbered syringes. The study medication in syringes for injection will be prepared by an anesthesiologist neither involved in the study nor in the care of the patient, before handing it over to the investigators. The ESB-group will receive 20 ml Chirocaine 0,25%. The sham block group medication will receive 20 ml Nacl0,9%. The levobupivacaine and saline 0.9% are identical in appearance. All investigators, staff and patients will be blinded to the treatment groups. Epinephrine is added to the placebo block in order to prevent unblinding by increased heart rate or blood pressure. Unmasking will not occur until statistical analysis is complete.
Patients in the erector spinae block group will receive a bilateral ESB block with an injectate containing 20 ml of levobupivacaine 0.25% in each puncture. Patients allocated to the sham group receive a bilateral ESB block with each injectate containing 20 mL of NaCl 0.9% . The blocks will be performed by experts in the field of ultrasound guided locoregional anaesthesia namely dr D. van Aken, dr L. Sermeus and dr M.B. Breebaart who are also teachers for the BARA (Belgian Association of Regional Anaesthesia). The blocks will be performed preoperatively in a separate block room with ultrasound after placement of an iv line and application of standard monitoring (ECG, NIBP, saturation). The blocks will be placed as described by Chin et al. modified for lumbar level.8 First, the patient will be placed in the lateral or sitting position. A curve array probe or a high frequency linear probe, depending on the BMI of the patient, will be placed in a longitudinal position 2-3 cm lateral of the vertebral column. The transverse processes of the vertebrae at the (mid) level of surgery, the erector spinae muscle and the psoas muscle are identified. In case of two level surgery the transverse process of the upper level will be considered as the preferred target. Depending on the depth a 5 or 8 cm 22 G ultrasound needle (Pajunk) will be inserted with an in plane technique in a cephalad to caudad direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, 20 ml of the study medication will be injected behind the erector spinae muscle. The same procedure will be repeated on the contralateral side.
General anesthesia will then be induced in a standardized way with propofol 2-3mg/kg, sufentanil 15mcg and rocuronium 0.5mg/kg. After tracheal intubation anesthesia will be maintained with sevoflurane and intraoperative analgesia with sufentanil. The dosages of these agents will be determined at the discretion of the anesthesiologist. At the end of surgery patients will receive acetaminophen 1g IV, ketorolac (Taradyl, CSP Benelux) 0.5 mg/kg (max. 30 mg) IV and a morphine loading dose (0.1 mg/kg) IV to manage postoperative pain. Patients will be extubated in the operating theatre and admitted to the post anesthesia care unit (PACU). Postoperative pain in the PACU and on the ward will be treated with acetaminophen 1g IV round the clock (4 times daily) and by a patient controlled intravenous analgesia pump (PCIA) with morphine at a concentration of 1 mg/ml and dehydrobenzperidol (DHBP) 0.05 mg/ml. The PCIA will be set using a standardised protocol: no background administration of morphine, a bolus dose of 1.5 mL morphine with a lock-out interval of 8 minutes and an hourly limit of 7.5 mg. If pain management on the PACU is inadequate (NRS > 3) additional boli of 1 mg morphine IV will be administered with the total additional dose of morphine limited to 0.15mg/kg morphine. In case NRS is still > 3 an IV ketamine (Ketalar, Pfizer) bolus (0.2 mg/kg) will be given. All patients receive dexamethasone 5mg IV as postoperative nausea and vomiting (PONV) prophylaxis. If needed, this will be supplemented by ondansetron 4mg IV and if still insufficient with alizapride 50mg IV. Other study endpoints will be retrieved from the patient data management systems
The morphine consumption during the first 24 hours postoperatively will be extracted out of the PCIA pump. The total morphine dose requirement during the first 72 postoperative hours will also be extracted out of the PCIA pump. Pain scores at rest will be assessed with the numeric rating scale (NRS, 0=no pain 10= worst imaginable pain) and tested at regular time intervals: at the time of inclusion, at the PACU (T0 = arrival at Post Anesthesia Care Unit, T+15min, T+30min) and ward (twice daily- morning and evening until postoperative day 3) Pain scores during defined movement (first moving to chair and upright sitting) will be examined. Time to first mobilization in chair (in hours since T0) and time to first walk of twenty meters (in hours since T0) will be noted in the patients study diary. The quality of recovery 40 score (QoR-40) will be calculated out of a series of questions patients are required to answer at day 1 and 3 postoperatively. The QoR-40 is a widely used and extensively validated measure of quality of recovery. It is a 40-item questionnaire on quality of recovery from anesthesia, that has been shown to measure health status after surgery.
5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.
This study's planned enrollment of 80 is close to the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.
Browse Pain, Postoperative studies →This is the only study on the registry with Dr M. B. Breebaart as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Erector Spinae plane block with 20 ml levobupivacaine 0,25% on each side. General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane. Postoperative analgesia with Ketorolac (0,5 mg/kg), paracetamol 1000 mg (4 times/ day) and Morphine PCA. Dexamethasone is administered for the prevention of nausea.
Procedure: Erector spinae plane block · Drug: Levobupivacaine 0,25% · Procedure: spine fusion · Drug: Sufentanil · Drug: propofol · Drug: Rocuronium Bromide · Drug: sevoflurane · Drug: paracetamol · Drug: Ketorolac · Drug: morphine pca · Drug: Dexamethasone · Drug: Morphine
Erector Spinae plane block with 20 ml NaCl 0,9% on each side General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.Postoperative analgesia with Ketorolac (0,5 mg/kg, paracetamol 1000 mg 4times/ day and Morphne PCA .Dexamethasone is administered for the prevention of nausea.
Procedure: Erector spinae plane block · Procedure: spine fusion · Drug: NaCL 0,9% · Drug: Sufentanil · Drug: propofol · Drug: Rocuronium Bromide · Drug: sevoflurane · Drug: paracetamol · Drug: Ketorolac · Drug: morphine pca · Drug: Dexamethasone · Drug: Morphine
Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle
Also known as: Locoregional anaesthesia
20 ml levobupivacaine 0,25% used for the infiltration between the transverse process and the erector spinal muscle
Also known as: chirocaine
fusion of lumbar vertebral body on 1 or two levels
20 ml solution used for the infiltration between the transverse process and th erector spinal muscle
opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
Also known as: sufenta
induction agent for general anaesthesia ( 2-3 mg/kg)
muscle relaxant used during general anaesthesia ( 0,5 mg/kg)
Also known as: sermon
inhalation aesthetic used for the maintenance of general anaesthesia
postoperative drug for analgesia ( 1 gram 4/day)
non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml
Also known as: patient controlled analgesia
drug given during general anaesthesia to prevent postoperative nausea
Also known as: aacidexam
loading dose morhine 0,1 mg/kg at the end of surgery
24 hour morphine consumption
total milligrams (0-150) of morphine used in the first 24 hours after surgery, extracted out of the pca pump data.
Time frame: 24 hours
Intraoperative sufentanyl requirement (
total Intravenous administered sufentanyl in micrograms during surgery(10-100)
Time frame: 2-5 hours
Morphine consumption 72 hours
total milligrams of morphine used in 72 hours after surgery (0-450), extracted out of the pca pump data
Time frame: 72 hours
NRS pain scores
Numeric rating scale pain score (in numbers) and rest (0= no pain10 =worst thinkable pain)
Time frame: at regular intervals and defined movement until 72 hours after surgery
Quality of recovery score (QoR-40)
score in numbers of mental and psychological well being scored by list of questions (minimal score 20-maximum score 200). A high score indicates a better/faster recovery, and is inversely correlated with hospital stay
Time frame: day 1 and day 3 postoperatively
time to mobilisation to chair
movements (mobilisation to chair) in hours after surgery
Time frame: 8-72 hours
time to 20 meter walking
movement 20 meter walking in hours after surgery
Time frame: 8-72 hours
expected preoperative pain score (NRs°
Numeric rating scale pain score (in numbers). pain that people expect before they have surgery.
Time frame: before surgery ( moment of inclusion)
Plan to share: No
This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.